Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Trial details
- Registry ID
- NCT02492711
- Phase
- Phase 3
The FDA approved Margetuximab (MGAH22) on 16 Dec 2020.
Drug identity checked against registry records
Also recorded as MGAH22; Margenza®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 | MacroGenics | Phase 3 | Completed | 2021-08-11Actual |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCNCT04262804 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Unknown | 2021-09-03Actual |
| Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerNCT01828021 | MacroGenics | Phase 2 | Completed | 2016-12-07Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-12-16Day | Margetuximab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761150", "applicant_as_listed_by_fda": "TERSERA THERAPEUTICS LLC", "brand_names": ["MARGENZA"], "active_ingredients": ["MARGETUXIMAB-CMKB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20201216", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |